Bristol Myers Squibb (NYSE: BMY) today announced the presentation of data across its oncology and hematology portfolio at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
First presentation of results from primary analysis of Phase 2 TRANSCEND FL study evaluating second-line treatment with Breyanzi® in relapsed or refractory follicular lymphoma demonstrate its.